MEX:HZNP (Ireland)  
Horizon Therapeutics PLC logo

Horizon Therapeutics PLC

MXN 2164.00 (0%) Feb 1
P/E:
45.27
P/B:
5.02
Market Cap:
MXN 475.47B ($ 25.64B)
Enterprise V:
MXN 483.19B ($ 26.05B)
Volume:
-
Avg Vol (2M):
4.12K
Also Trade In:
Volume:
-
Market Cap MXN:
475.47B
Market Cap $:
25.64B
PE Ratio:
45.27
Avg Vol (2-Month):
4.12K
Enterprise Value MXN:
483.19B
Enterprise Value $:
26.05B
PB Ratio:
5.02

Business Description

Description
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 0.84
Equity-to-Asset 0.56
Debt-to-Equity 0.51
Debt-to-EBITDA 2.42
Interest Coverage 8.43
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.88
Distress
Grey
Safe
Beneish M-Score -2.97
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 18.35
9-Day RSI 60.56
14-Day RSI 76.21
6-1 Month Momentum % 27.96
12-1 Month Momentum % 18.55

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.96
Quick Ratio 3.74
Cash Ratio 2.5
Days Inventory 85.9
Days Sales Outstanding 67.3
Days Payable 15.74

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -10.4